Figure 2.

CTRP9 supplementation enhances perfusion of ischemic limbs in WT and CTRP9-KO mice. (A) CTRP9 expression in plasma in WT and CTRP9-KO mice after treatment with Ad-CTRP9 or Ad-β-gal (control). Ad-CTRP9 or Ad-β-gal was injected into the jugular vein of WT and CTRP9-KO mice (7 × 10⁸ ifu in each group) at day 5 before surgery. Plasma CTRP9 levels were assessed at day 5 after adenoviral vector injection by Western blot analysis. (B) Quantitative analysis of ischemic to nonischemic laser Doppler blood flow (LDBF) ratio in WT and CTRP9-KO mice receiving Ad-β-gal or Ad-CTRP9 on postoperative day 14 (n = 4–9 mice for each group). (C) Quantitative analysis of capillary density in WT and CTRP9-KO mice receiving Ad-β-gal or Ad-CTRP9. Capillary density was expressed as the number of capillaries per muscle fiber. Results are presented as mean ± SD (n = 3 mice for each group).